AbbVie Inc. $ABBV Position Lowered by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 383,600 shares of the company’s stock after selling 37,698 shares during the period. Thrivent Financial for Lutherans’ holdings in AbbVie were worth $87,668,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Chelsea Counsel Co. bought a new position in AbbVie in the third quarter worth about $26,000. Westend Capital Management LLC bought a new position in AbbVie in the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie in the third quarter worth about $31,000. Legacy Wealth Managment LLC ID lifted its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC lifted its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by company insiders.

AbbVie Trading Down 0.1%

ABBV opened at $210.54 on Friday. AbbVie Inc. has a twelve month low of $180.25 and a twelve month high of $244.81. The stock has a market cap of $371.97 billion, a PE ratio of 103.71, a price-to-earnings-growth ratio of 0.73 and a beta of 0.32. The business’s 50 day moving average is $210.27 and its 200-day moving average is $220.10.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the business earned $2.46 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, analysts forecast that AbbVie Inc. will post 14.32 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date was Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

Analyst Ratings Changes

A number of brokerages have issued reports on ABBV. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Barclays began coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.43.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.